Granted Patent B2

US 12,486,514 · App. 17/267,617 · Granted Dec 2, 2025

Inventors: Natasha Vinanica (Singapore, SG); Arthur Yong (Singapore, SG); Dario Campana (Singapore, SG); Masaru Imamura (Niigata, JP)

Assignee: National University of Singapore

C12N15/625A61K40/11A61K40/31A61K40/4201A61K40/4211A61P35/02C07K14/7051C07K14/72C07K16/2803C12N5/0636C12N15/85A61K38/00A61K2239/31A61K2239/38A61K2239/48

Abstract

Claims (30)

1 . A mammalian T cell comprising a vector, the vector comprising a nucleic acid encoding:

a) an erythropoietin (Epo) receptor;

b) a 2A peptide; and

c) a chimeric antigen receptor comprising:

i) a signal peptide;

ii an extracellular receptor domain that binds CD19;

iii) a hinge and transmembrane domain that anchors the extracellular receptor domain on the surface of a cell; and

iv) an effector domain;

wherein the Epo receptor is expressed on the mammalian T cell surface, and

wherein the nucleic acid encodes SEQ ID NO: 12.

2 . A method of making a transgenic mammalian T cell, the method comprising introducing a vector into a mammalian T cell, the vector comprising a nucleic acid encoding:

a) an erythropoietin (Epo) receptor;

b) a 2A peptide; and

c) a chimeric antigen receptor comprising:

i) a signal peptide;

ii) an extracellular receptor domain that binds CD19;

iii) a hinge and transmembrane domain that anchors the extracellular receptor domain on the surface of the mammalian T cell; and

iv) an effector domain;

wherein the Epo receptor is expressed on the mammalian T cell surface, and

wherein the nucleic acid encodes SEQ ID NO: 12.

3 . The method of claim 2 , wherein the mammalian T cell further expresses a T-cell receptor (TCR) that binds a tumor antigen or a viral antigen.

4 . The method of claim 3 , wherein the TCR is endogenous.

5 . The method of claim 4 , wherein the mammalian T cell is a tumor-infiltrating lymphocyte (TIL), and wherein the method further comprises extracting the tumor-infiltrating lymphocyte from a tumor and expanding the TIL ex vivo.

6 . The mammalian T cell of claim 1 , wherein the mammalian T cell is a human T cell.

7 . The mammalian T cell of claim 1 , wherein the mammalian T cell is a human peripheral blood T lymphocyte.

8 . The mammalian T cell of claim 1 , wherein the mammalian T cell expresses a T-cell receptor (TCR) that binds a tumor antigen or a viral antigen.

9 . The mammalian T cell of claim 8 , wherein the TCR is endogenous.

10 . The mammalian T cell of claim 9 , wherein the mammalian T cell is a tumor-infiltrating lymphocyte (TIL).

11 . The mammalian T cell of claim 1 , wherein the mammalian T cell is a CD8+ T cell.

12 . The method of claim 2 , wherein the mammalian T cell is a CD8+ T cell.

Assignments (1)

Continuity (2)

References Cited (400)